Frailty and anticoagulants in older subjects with atrial fibrillation: the EUROSAF study
Alberto Pilotto,Nicola Veronese,Maria Cristina Polidori,Timo Strandberg,Eva Topinkova,Alfonso J Cruz-Jentoft,Carlo Custodero,Mario Barbagallo,Stefania Maggi,EUROSAF Study Investigators,Alberto Ferri,Alessandra Argusti,Federica Gandolfo,Clarissa Musacchio,Katerin Leslie Quispe Guerrero,Vincenzo Solfrizzi,Carlo Sabbà,Joshua Verleysdonk,Nico Noetzela,Juhani Rossinen,Laura Pikkarainen,Tuomo Nieminen,Helena Michalkova,Pavla Madlova,Lucie Bautzka,Stefania,Nicola Ferrara,Lucia Gioia,Anna Maria Iannicelli,Giovanna Di Bella,Federica Cacioppo,Giovanni Ruotolo,Alberto Castagna,Regina Roller-Wirnsberger,Christian Sebesta,Sonja Lindner,Alfonso Cruz-Jentoft,Luisa A Hernandez-Sanchez,Jana Albeniz Lopez,Genesis Estefanıa Olaya-Loor,Pedro Marques da Silva,Heidi Gruner,Jean Petermans,Sophie Gillain,Veronique Jonart,Ondrej Vyska,Jiri Nakladal,Katarina Bielakova,Hana Matejovska-Kubesova,Adrian Enica,Stephanie Roth,Benjamin Jacquet,Vito Curiale,Nicolas Berg,Livia Mirea Cimpeanu,Rafaela Verissimo,Leonor Silva,Luciana Silva,Pedro Magalhães,Gabriel Ioan Prada,Anna Marie Herghelegiu,Catalina Raluca Nuta,Blanca Garmendia-Prieto,Isabel Lozano-Montoya,Javier Jaramillo-Hidalgo,Javier Gomez-Pav,Ursula Müller-Werdan,Gordon Werth,Adrian Rosada,Ozlem Yilmaz,Sena Geurkaş Francesco Mattace-Raso
DOI: https://doi.org/10.1093/ageing/afad216
2023-11-02
Abstract:Aims: Literature regarding anticoagulants in older people affected by atrial fibrillation (AF) is limited to retrospective studies, poorly considering the importance of multidimensional frailty. The main objective of this study is to evaluate in hospitalised older persons with AF the benefit/risk ratio of the anticoagulant treatments, considering the severity of frailty, determined by the multidimensional prognostic index (MPI). Methods: In this European, multicentre, prospective study, older hospitalised patients (≥65 years) with non-valvular AF were followed-up for 12 months. Anticoagulants' use at discharge ascertained using medical records. MPI was calculated using tools derived from comprehensive geriatric assessment, classifying participants in robust, pre-frail or frail. Mortality (primary outcome); vascular events, including ischemic heart disease or ischemic stroke, hemorrhagic stroke or gastrointestinal bleedings (secondary outcomes). Results: 2,022 participants (mean age 82.9 years; females 56.6%) were included. Compared with people not taking anticoagulants (n = 823), people using vitamin K antagonists (n = 450) showed a decreased risk of mortality (hazard ratio, HR = 0.74; 95% CI: 0.59-0.93), more pronounced in patients using direct oral anticoagulants (DOACs) (n = 749) (HR = 0.46; 95% CI: 0.37-0.57). Only people taking DOACs reported a significantly lower risk of vascular events (HR = 0.55; 95% CI: 0.31-0.97). The efficacy of DOACs was present independently from frailty status. The risk of gastrointestinal bleedings and hemorrhagic stroke did not differ based on the anticoagulant treatments and by MPI values. Conclusions: Anticoagulant treatment, particularly with DOACs, was associated with reduced mortality in older people, without increasing the risk of hemorrhagic events, overall suggesting the importance of treating with anticoagulants older people with AF.